TLE family member 4, transcriptional corepressorGenealiases: BCE-1 · BCE1 · E(spI) · E(spl) · ESG · ESG4
Q-omics provides the consensus-scored TLE4 profile across patient tissues and cancer cell-line models. TLE4 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, TLE4 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, TLE4 RNA expression shows 19,918 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight SKCM, KIRC, and THYM as cancer lineages where TLE4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TLE4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TLE4 survival associations across molecular data types. TLE4 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TLE4 RNA expression–survival associations across cancer types. High TLE4 expression shows unfavorable associations in LGG and ACC, but favorable associations in SKCM, KIRP, CESC and KIRC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for TLE4 RNA expression.
This table summarizes TLE4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TLE4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TLE4 shows lower tumor expression in KIRC, THCA, LUAD, COAD and UCEC and higher tumor expression in HNSC. The KIRC box plot shows higher TLE4 RNA expression in normal versus tumor tissue (log2 FC = −0.960, t-test p < 0.001).
This table shows molecular features associated with TLE4 in patient tissues and cancer cell lines. In patient samples, TLE4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TLE4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
